Skip to content

Company

Johnson & Johnson

American pharmaceutical and medical technology company, formerly also a large consumer health products maker.

Known aliases

  • J&J
  • Johnson and Johnson

Current stories

scienceOne report1 publisher

Compass Pathways CEO wants a slow COMP360 launch to protect the psychedelics field

Compass Pathways expects to complete its rolling FDA submission for COMP360 this quarter and launch early next year, CEO Kabir Nath said. He wants a slow, provider-trained rollout under an expected REMS, because early bad experiences could damage the broader sector.

Publishers:statnews.com

Reality

Evidence50
Adoption
Not scored
Hype gap+10
Incentives60
Confidence55
investOne report1 publisher

Yuhan's lazertinib royalties are expected to top 40 billion won on J&J sales up 62.3%

Yuhan is expected to collect over 40 billion won in lazertinib royalties this year after J&J's combined Q3 sales rose 62.3% to $320 million. Shinhan Securities projects 507 billion won a year by 2040, with 40% going to Oscotec, the original developer.

Publishers:en.sedaily.com

Reality

Evidence40
Adoption55
Hype gap+30
Incentives
Not scored
Confidence45
investConfirmed5 publishers

Isomorphic Labs seeks a $40 billion valuation before its first human trial

Alphabet's Isomorphic Labs is in funding talks at a $40 billion valuation. Crypto Briefing put its prior mark near $17.5 billion, so the ask more than doubles the price of a drug designer that has yet to dose a patient.

Perspective Coverage

6 publishers
Builder
Builder 26%
Operator
Operator 17%
Investor
Investor 57%

Reality

Evidence55
Adoption25
Hype gap+45
Incentives55
Confidence55
leadershipOne report1 publisher

Meta's board opposed a 2018 privacy committee proposal a year before the FTC ordered one

Meta's board rejected a 2018 shareholder call to study a privacy risk committee a year before the FTC fined the company $5 billion, an ICCR memo says. Outside holders backed the request at 45%, but Mark Zuckerberg's voting control cut the recorded tally to 11.55%, so the board's win mostly measured his vote.

Reality

Evidence40
Adoption
Not scored
Hype gap+35
Incentives65
Confidence45
investOne report1 publisher

Ayala's first outsider CEO answers the break-up playbook with a dividend demand

Cezar Consing is keeping the Philippine group whole while telling its units to send more cash to the centre, which is break-up discipline run internally, and the comparison he has to beat is GE's 7.7-fold market value since 2018.

Publishers:fortune.com

Reality

Evidence44
Adoption38
Hype gap+24
Incentives72
Confidence55